KLF10 and cholangiocarcinoma: More importantly, when co-transfected to gemcitabine-resistant cholangiocarcinoma cells, the effects of si-KLF10 were significantly reversed by EGFR silencing, indicating that KLF10 participates in the inhibition of PDT on gemcitabine-resistant cholangiocarcinoma cells through EGFR.